Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 438,770	$ 13,663	$ 607,801	$ 40,990	$ 54,653
Amortization of license agreements remainder of fiscal year 2015	438,771		438,771
Amortization of license agreements in 2016	1,714,313		1,714,313
Amortization of license agreements in 2017	1,700,429		1,700,429
Amortization of license agreements in 2018	1,700,429		1,700,429
Amortization of license agreements in 2019	1,700,429		1,700,429
Amortization of license agreements in 2020	1,700,429		1,700,429
Amortization of license agreements, thereafter	15,363,151		$ 15,363,151
Novartis | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			21 years
Finite-lived intangible assets, accumulated amortization	49,468		$ 49,468
Novartis | Patents [Member]
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			14 years
Finite-lived intangible assets, accumulated amortization	517,341		$ 517,341
Roche Madison [Member] | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Amortization period of intangible assets			4 years
Finite-lived intangible assets, accumulated amortization	$ 202,453		$ 202,453